First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Related Posts
Jo J, Boltz AJ, Williams KL, Pasquina PF, McAllister TW, McCrea MA, Broglio SP, Zuckerman SL, Terry DP; CARE Consortium Investigators; Arbogast K, Benjamin HJ,[...]
Shin DS, Basak S, Veena MS, Comin-Anduix B, Bhattacharya A, Dong TS, Ko A, Han P, Jacobs J, Moatamed NA, Avila L, Pellegrini M, Wang[...]
Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry[...]